国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (12): 892-895.doi: 10.3760/cma.j.issn.1673422X.2016.12.003

• 论著 • 上一篇    下一篇

TRAF6在胃癌患者腹直肌中的表达及意义

钱晓宇, 唐坚, 徐言, 李琳, 孙元水   

  1. 浙江省嘉兴市第一医院肿瘤外科
  • 出版日期:2016-12-08 发布日期:2016-11-02
  • 基金资助:

    浙江省科技厅项目（2013C33203）；嘉兴市普通外科重点学科基金（04-F-15）

Expression and significance of TRAF6 in rectus abdominis of gastric cancer patients

 Qian-Xiao-Yu, TANG  Jian, XU  Yan, LI  Lin, SUN  Yuan-Shui   

  1. Department of Surgical Oncology, First Hospital of Jiaxing, Zhejiang Province, Jiaxing 314000, China
  • Online:2016-12-08 Published:2016-11-02
  • Supported by:

    Project of Science and Technology Department of Zhejiang Province (2013C33203); Project of Key Subject Foundation of Jiaxing General Surgery (04-F-15)

PDF

1111

摘要： 目的 分别检测各期胃癌患者和腹腔良性疾病患者腹直肌中肿瘤坏死因子受体相关因子6（TRAF6）的表达情况，分析其表达的差异性，并进一步探讨TRAF6与胃癌患者营养状况及预后的关系。方法 应用实时荧光定量PCR和Western blotting检测TRAF6在64例各期胃癌患者和53例腹腔良性疾病患者腹直肌中的表达情况，并与患者临床数据相结合，探讨其表达的意义。结果 与腹腔良性疾病患者相比（1.249±0.723），Ⅰ期（2.080±0.611）、Ⅱ期（2.126±0.640）、Ⅲ期（3.127±0.953）、Ⅳ期（3.289±0.734）胃癌患者腹直肌中TRAF6 mRNA的表达显著升高，差异有统计学意义（t=4.107，P=0.001；t=4.128，P=0.000；t=8.741，P=0.000；t=9.208，P=0.000）。与腹腔良性疾病患者相比（0.088±0.013），Ⅰ期（0.198±0.042）、Ⅱ期（0.209±0.051）、Ⅲ期（0.295±0.072）、Ⅳ期（0.345±0.084）胃癌患者腹直肌中TRAF6蛋白的表达显著升高，差异有统计学意义（t=5.203，P=0.000；t=5.642，P=0.000；t=9.351，P=0.000；t=9.854，P=0.000）。TRAF6 mRNA在67.2%（43/64）的胃癌患者腹直肌组织中呈高表达。TRAF6 mRNA的表达与胃癌患者体质量下降百分比（χ2=12.231，P=0.000）、白蛋白水平（χ2=22.808，P=0.000）显著相关。TRAF6 mRNA在胃癌患者腹直肌中的表达与生存率显著相关（χ2=3.933，P=0.047）。结论TRAF6在胃癌患者腹直肌中呈高表达，可能在胃癌患者恶病质的发生、发展过程中发挥关键性作用，其高表达提示预后不良。

关键词: 胃肿瘤, 腹直肌, 恶病质, 肿瘤坏死因子受体相关因子-6

Abstract: ObjectiveTo research the expression of tumor necrosis factor receptorassociated factor 6 (TRAF6) in rectus abdominis of gastric cancer patients and abdominal benign disease patients, and discuss the relationship between nutritional status and prognosis of gastric cancer patients with TRAF6. MethodsBiopsies of the rectus abdominis were obtained intraoperatively from 64 gastric cancer patients and 53 subjects undergoing surgery for benign abdominal diseases. The expression levels of TRAF6 mRNA and protein were assessed through quantitative real time reverse transcriptase PCR (RTQPCR) and Western blotting, and the relationships between nutritional status and prognosis of gastric cancer patients and the expression status of TRAF6 were analyzed. ResultsTRAF6 mRNA was significantly upregulated in muscle of stage Ⅰ (2.080±0.611), stage Ⅱ (2.126±0.640), stage Ⅲ (3.127±0.953), stage Ⅳ (3.289±0.734) gastric cancer compared with the control group (1.249±0.723), t=4.107, P=0.001; t=4.128, P=0.000; t=8.741, P=0.000; t=9.208, P=0.000. TRAF6 protein was significantly upregulated in muscle of stage Ⅰ (0.198±0.042), stage Ⅱ (0.209±0.051), stage Ⅲ (0.295±0.072), stage Ⅳ (0.345±0.084) gastric cancer compared with the control group (0.088±0.013), t=5.203, P=0.000; t= 5.642, P=0.000; t=9.351, P=0.000; t=9.854, P=0.000. TRAF6 was upregulated in 67.2% (43/64) of gastric cancer patients. The expression of TRAF6 in muscles of gastric cancer was associated with the percent of weight loss (χ2=12.231, P=0.000), the level of serum albumin (χ2=22.808, P=0.000) and the survival rate (χ2=3.933, P=0.047). ConclusionTRAF6 is significantly upregulated in rectus abdominis of gastric cancer, suggesting that TRAF6 may play an important role in progression and prognosis of cancer cachexia, and its overexpression suggests unfavorable prognosis.

Key words: Stomach neoplasms, Rectus abdominis, Cachexia, Tumor necrosis factor receptorassociated factor 6